Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-5737 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GS-5737 | ACTIVE_COMPARATOR | The GS-5737 85 μg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline. |
| Placebo | PLACEBO_COMPARATOR | The vehicle (placebo) control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL. |
| Name | Type | Description |
|---|---|---|
| GS-5737 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Males or females, ≥ 18 years of age, at Screening * Diagnosis of CF as determined by the 1997 CF Consensus Conference criteria, with at least 1 of the following: Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test OR Abnormal nasal transepitheli...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
GS-5737 is an investigational small molecule being studied for the treatment of cystic fibrosis. It is being developed by Gilead Sciences, Inc. (GILD) and has completed a Phase 1b clinical trial in patients with cystic fibrosis. The drug is not yet approved and remains in clinical development.
GS-5737 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker GILD. Gilead is conducting clinical research to evaluate the safety and tolerability of GS-5737 in patients with cystic fibrosis.
GS-5737 is in Phase 1 clinical development. A Phase 1b trial has been completed, which was designed to assess the safety, tolerability, and pharmacokinetics of the drug in subjects with cystic fibrosis. The drug is investigational and has not received FDA approval.
GS-5737 has one completed clinical trial, identified as NCT01840735. This was a Phase 1b study titled 'Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF.' The trial enrolled 8 participants in the United States and was a randomized, double-blind, placebo-controlled study.
No, GS-5737 is not the same as remdesivir. GS-5737 is being studied for cystic fibrosis, while remdesivir is a different antiviral drug. The two are distinct investigational compounds with different mechanisms and clinical applications.